A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

As of now, semaglutide is not approved to treat MASH, and the maker Novo Nordisk has plans to seek regulatory approval for ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...